posted on 2021-01-22, 20:54authored byBradley Q. Fox, Peninah F. Benjamin, Ammara Aqeel, Emily Fitts, Spencer Flynn, Brian Levine, Elizaveta Maslak, Rebecca L. Milner, Benjamin Ose, Michael Poeschla, Meghna Ray, Maeve Serino, Sahaj S. Shah, Kelly L. Close
Despite the growing momentum behind a movement to augment adoption
of continuous glucose monitoring (CGM) in clinical practice and investigation,
to the best of our knowledge, there are no published data on the historical and
recent use of CGM in clinical trials of pharmacologic agents used in the
treatment of diabetes. We analyzed 2,032 clinical trials of 40 diabetes
therapies currently on the market with a study start date between 1 January
2000 and 31 December 2019. According to ClinicalTrials.gov listings, 119 (5.9%)
of these trials used CGM. CGM usage in clinical trials has increased over time,
rising from <5% before 2005 to 12.5% in 2019. However, it is still low given
its inclusion in the American Diabetes’s Association’s latest guidelines and known
limitations of A1C for assessing ongoing diabetes care.